Daré Bioscience, Inc.
General ticker "DARE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $28.8M (TTM average)
Daré Bioscience, Inc. does not follow the US Stock Market performance with the rate: -13.1%.
Estimated limits based on current volatility of 1.8%: low 0.71$, high 0.74$
Factors to consider:
- Total employees count: 21 (0.0%) as of 2025
- Top business risk factors: Insufficient capital, Clinical trial failure, Regulatory and compliance, Key person loss, Market volatility
- Current price 63.2% below estimated low
- Earnings for 18 months up through Q2 (+1 year) are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.85$, 5.48$]
- 2025-12-31 to 2026-12-31 estimated range: [1.97$, 5.62$]
Financial Metrics affecting the DARE estimates:
- Positive: with PPE of -6.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Positive: 15.29 < Operating cash flow per share per price, % of 20.48
- Positive: Interest expense per share per price, % of 0 <= 0
- Positive: -2.60 < Investing cash flow per share per price, % of -2.14
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: -28.70 < Return on assets ratio (scaled to [-100,100]) of -15.50
Short-term DARE quotes
Long-term DARE plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $10.00MM | $2.81MM | $0.01MM |
| Operating Expenses | $41.39MM | $33.75MM | $23.46MM |
| Operating Income | $-31.39MM | $-30.94MM | $-23.45MM |
| Non-Operating Income | $0.44MM | $0.78MM | $19.40MM |
| R&D Expense | $30.04MM | $21.54MM | $14.21MM |
| Income(Loss) | $-30.95MM | $-30.16MM | $-4.05MM |
| Net Income(Loss)* | $-30.95MM | $-30.16MM | $-4.05MM |
| Stockholders Equity | $11.11MM | $-5.05MM | $-6.01MM |
| Assets | $43.83MM | $21.28MM | $22.10MM |
| Operating Cash Flow | $-18.09MM | $-38.86MM | $5.47MM |
| Capital expenditure | $0.06MM | $0.63MM | $0.57MM |
| Investing Cash Flow | $-0.06MM | $-0.63MM | $-0.57MM |
| Financing Cash Flow | $1.34MM | $15.64MM | $0.35MM |
| Earnings Per Share** | $-4.39 | $-4.15 | $-0.48 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.